

1. Popolazioni studiate - Funzionalità renale



* Apixaban non ha ancora ottenuto la MA per l'indicazione SPAF in nessun Paese




1. Popolazioni studiate

- Trattamento antiaggregante

	ASA	CLOPIDOGREL	ASA+ CLOPIDOGREL
	40%	6%	4%
	37%	n.d.	
	31%	2%	

1. Popolazioni studiate

- Trattamento VKA al basale



1. Popolazioni studiate

- CHADS₂

CHADS₂= 0-1

CHADS₂= 2

CHADS₂≥ 3



32%

36%

32%



0%

13%


87%



34%

36%

30%




CHADS₂ Score

Evaluated in non valvular AF, 4845 pts


		Clinical Setting		
	Total (n. 4845)	Cardiology (n. 2499)	Internal Medicine (n. 2346)	p
0, %	36.1	13.8	5.2	<.0001
1, %		33.1	19.5	
≥2, %	63.9	53.1	75.3	

2. EFFICACIA (RRR% vs W)



*dati on treatment; † non comprende ictus n.c.


2. EFFICACIA (RRR% vs W)



*dati on treatment

Pradaxa
dabigatran etexilato
Simply superior stroke prevention
Simply superior stroke prevention

2. EFFICACIA (RRR% vs W)



*dati on treatment; † non comprende ictus n.c.

3. SICUREZZA (RRR% vs W)

		Sanguinamenti totali	Sanguinamenti intracranici	Sanguinamenti maggiori	Sanguinamenti pericolosi per la vita
	150mg BID	-9	-59	-7	-20
	110mg BID	-22	-70	-20	-33
	20mg OD	+3*	-33*	+4*	
	5mg BID	-29	-58	-31	

*dati on treatment per la "safety population" come da protocollo

3. SICUREZZA

- Età e sanguinamenti maggiori

